What to Expect From Arena Pharmaceuticals, Inc. (ARNA)’s Launch of Belviq

Either way, even achieving half of this goal blows Wall Street’s expectations out of the water and puts Jefferies’ target in the “upside scenario” which calls for a price target of $33. At the same time there is a 57 million share short interest which has purportedly been trying to cap Arena’s stock price with a number of reverse conversions (use of market maker naked short exemption). Despite a 7 million share drop in short interest, shorts need to cover a lot more shares in light of expected robust sales of Belviq. Institutional interest in ARNA has risen to 47% including increase in the holding of even the most conservative firms like Credit Suisse which estimates Belviq to become a blockbuster. For Motley Fool’s take on both companies, please download the reports below.

REZA GANJAVI owns shares of Arena Pharmaceuticals.

The  opinions above are not investment advice and are not medical advice.The Motley Fool has no position in any of the stocks mentioned.

The article What to Expect From Arena Pharmaceuticals’ Launch of Belviq originally appeared on Fool.com and is written by REZA GANJAVI.

REZA is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.